Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice

被引:11
|
作者
Chu-LaGraff, Q
Kang, XW
Messer, A
机构
[1] New York State Dept Hlth, Wadsworth Ctr Labs & Res, David Axelros Inst, Albany, NY 12201 USA
[2] Union Coll, Dept Biol, Schenectady, NY 12308 USA
[3] SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA
关键词
neural stem cells; Huntington's disease; transgenic; neurons; glia; neurospheres; differentiation;
D O I
10.1016/S0361-9230(01)00598-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is an inherited neurodegenerative disorder resulting in neuronal cell death in discrete brain regions due to an expanded CAG repeat of the huntingtin gene. The transgenic mouse model R6/2 expresses exon 1 of the human huntingtin gene with > 150 CAG repeats, which produces mutant HD protein with an expanded poly-glutamine tract. We have established a neuronal stem cell system deriving from transgenic HD R6/2 neonatal brains as a renewable source for neurons and glia to facilitate studies of HD neuropathology and therapies. These R6/2 stem cell cultures can be cryopreserved and revived. Thawed neural progenitors can be expanded, established as continuous cell lines, and induced to differentiate into glia and neurons. Using standard culture conditions, there was no detectable morphological difference between wild type and HDR6/2 cells. Western analysis reveals that R6/2, but not wild type neurospheres, express the expanded repeat transgenic protein. Immunocytochemistry reveals that at a higher antibody concentration, huntingtin can be localized in the nucleus and the cytoplasm of wild type and R6/2 cells. We conclude that the R6/2 neuronal stem cell culture is a valuable tool for investigating HD pathogenesis and potential genetic or pharmacological interventions. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 50 条
  • [21] Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice
    Bolivar, VJ
    Manley, K
    Messer, A
    BEHAVIORAL NEUROSCIENCE, 2003, 117 (06) : 1233 - 1242
  • [22] Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease
    Decressac, M.
    Wright, B.
    Tyers, P.
    Gaillard, A.
    Barker, R. A.
    EXPERIMENTAL NEUROLOGY, 2010, 226 (01) : 24 - 32
  • [23] Catecholamine exocytosis is diminished in R6/2 Huntington's disease model mice
    Johnson, Michael A.
    Villanueva, Melissa
    Haynes, Christy L.
    Seipel, Andrew T.
    Buhler, Leah A.
    Wightman, R. Mark
    JOURNAL OF NEUROCHEMISTRY, 2007, 103 (05) : 2102 - 2110
  • [24] Hyperkinetic and rigid gait in R6/2 mice, a model of Huntington's disease
    Hampton, T. G.
    Kale, A.
    McCue, S.
    Amende, I.
    MOVEMENT DISORDERS, 2008, 23 (01) : S185 - S185
  • [25] Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice
    Stack, Edward C.
    Dedeoglu, Alpaslan
    Smith, Karen M.
    Cormier, Kerry
    Kubilus, James K.
    Bogdanov, Mikhail
    Matson, Wayne R.
    Yang, Lichuan
    Jenkins, Bruce G.
    Luthi-Carter, Ruth
    Kowall, Neil W.
    Hersch, Steven M.
    Beal, M. Flint
    Ferrante, Robert J.
    JOURNAL OF NEUROSCIENCE, 2007, 27 (47): : 12908 - 12915
  • [26] A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse
    Batista, Claudia M. C.
    Kippin, Tod E.
    Willaime-Morawek, Sandrine
    Shimabukuro, Marilia Kimie
    Akamatsu, Wado
    van der Kooy, Derek
    JOURNAL OF NEUROSCIENCE, 2006, 26 (41): : 10452 - 10460
  • [27] Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice
    Klapstein, GJ
    Levine, MS
    JOURNAL OF NEUROPHYSIOLOGY, 2005, 93 (02) : 758 - 765
  • [28] Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice
    Di Pardo, A.
    Carrizzo, A.
    Damato, A.
    Castaldo, S.
    Amico, E.
    Capocci, L.
    Ambrosio, M.
    Pompeo, F.
    De Sanctis, C.
    Spinelli, C. C.
    Puca, A. A.
    Remondelli, P.
    Maglione, V.
    Vecchione, C.
    SCIENTIFIC REPORTS, 2017, 7
  • [29] Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
    Stack, EC
    Smith, KM
    Ryu, H
    Cormier, K
    Chen, MH
    Hagerty, SW
    Del Signore, SJ
    Cudkowicz, ME
    Friedlander, RM
    Ferrante, RJ
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2006, 1762 (03): : 373 - 380
  • [30] Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice
    Liévens, JC
    Woodman, B
    Mahal, A
    Bates, GP
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2002, 20 (04) : 638 - 648